The first preclinical study of a new Rice Univ.-developed anticancer technology found that a novel combination of existing clinical treatments can instantaneously detect and kill only cancer cells without harming surrounding normal organs. The research reports that Rice’s “quadrapeutics” technology was 17 times more efficient than conventional chemoradiation therapy against aggressive, drug-resistant head and neck tumors.
Developmental biologists at Tufts Univ., using a tadpole model, have shown that bioelectrical signals from distant cells control the incidence of tumors arising from cancer-causing genes and that this process is impacted by levels of a common fatty acid produced by bacteria found in the tadpole and also in humans.
Biomedical engineering researchers have developed daisy-shaped, nanoscale structures that are made predominantly of anticancer drugs and are capable of introducing a “cocktail” of multiple drugs into cancer cells. The researchers are all part the joint biomedical engineering program at North Carolina State Univ. and the Univ. of North Carolina at Chapel Hill.
A pathway to the design of even more effective versions of the powerful anticancer drug Taxol has been opened with the most detailed look ever at the assembly and disassembly of microtubules, tiny fibers of tubulin protein that form the cytoskeletons of living cells and play a crucial role in mitosis.
Chemists at The Scripps Research Institute have determined the correct structure of a highly promising anticancer compound approved by the U.S. Food and Drug Administration for clinical trials in cancer patients. The new report, published in Angewandte Chemie, focuses on a compound called TIC10.
A new “lab-on-a-chip” platform developed at the Institute of Photonic Sciences in Spain is capable of detecting detect very low concentrations of protein cancer markers, enabling diagnoses of the disease in its earliest stages. The device, just a few square centimeters in size, uses recent advances in plasmonics, nano-fabrication, microfluids and surface chemistry.
Harvard Stem Cell Institute scientists have a potential solution for how to more effectively kill tumor cells using cancer-killing viruses. The investigators report that trapping virus-loaded stem cells in a gel and applying them to tumors significantly improved survival in mice with glioblastoma multiforme, the most common brain tumor in human adults and also the most difficult to treat.
Photodynamic therapy (PDT) is an effective treatment for easily accessible tumors such as oral and skin cancer. But the procedure, which uses lasers to activate special drugs called photosensitizing agents, isn’t adept at fighting cancer deep inside the body. That could change because of a new technology that could bring PDT into areas of the body which were previously inaccessible.
Fluorescent proteins have helped researchers open doors to countless molecular imaging applications and deepened our understanding of biological processes. Without fluorescence, advancements in oncology, drug discovery and any field that requires single-cell to whole-body imaging would be substantially limited.
Biomedical engineering researchers have developed an anti-cancer drug delivery method that essentially smuggles the drug into a cancer cell before triggering its release. The method can be likened to keeping a cancer-killing bomb and its detonator separate until they are inside a cancer cell, where they then combine to destroy the cell.
Massachusetts Institute of Technology researchers have devised a novel cancer treatment that destroys tumor cells by first disarming their defenses, then hitting them with a lethal dose of DNA damage. In studies with mice, the research team showed that this one-two punch, which relies on a nanoparticle that carries two drugs and releases them at different times, dramatically shrinks lung and breast tumors.
From time to time, genetic codes aren’t copied and collated properly, leaving gaps or breaks. A comprehensive mapping of these “fragile sites” in yeast by a team of Duke Univ. researchers shows that errors appear in specific areas of the genome where the DNA-copying machinery is slowed or stalled. The study could shed light on abnormalities seen in solid tumors.
Rice Univ. scientists have designed a tunable virus that works like a safe deposit box. It takes two keys to open it and release its therapeutic cargo. The Rice team developed an adeno-associated virus (AAV) that unlocks only in the presence of two selected proteases, enzymes that cut up other proteins for disposal. Because certain proteases are elevated at tumor sites, the viruses can be designed to target and destroy the cancer cells.
Using a mixture of cervical cancer cells and a hydrogel substance that resembles an ointment balm, Drexel Univ.’s Wei Sun can print out a tumor model that can be used for studying their growth and response to treatment. This living model will give cancer researchers a better look at how tumors behave and a more accurate measure of how they respond to treatment.
Federal health regulators have cleared a genetic test from Roche as the first ever U.S.-approved alternative to the Pap smear, the decades-old mainstay of cervical cancer screening. The U.S. Food and Drug Administration approved Swiss-based Roche's cobas HPV test to detect the human Papillomavirus, or HPV, in women 25 and up. HPV causes nearly all cases of cervical cancer.
A team at Purdue Univ. has used gold nanoparticles to target and bind to fragments of genetic material known as BRCA1 messenger RNA splice variants, which can indicate the presence and stage of breast cancer. The number of these synthetic DNA “tails” in a cell can be determined in a living cell by examining the specific signal that light produces when it interacts with the gold nanoparticles.
Purdue Univ. researchers have identified an important enzyme pathway that helps prevent new cells from receiving too many or too few chromosomes, a condition that has been directly linked to cancer and other diseases. The team found that near the end of cell division, the enzyme Cdc14 activates Yen1, an enzyme that ensures any breaks in DNA are fully repaired before the parent cell distributes copies of the genome to daughter cells.
Unlike healthy cells, cancer cells thrive when deprived of oxygen. Tumors in low-oxygen environments tend to be more resistant to therapy and spread more aggressively to other parts of the body. Measuring tumors’ oxygen levels could help doctors make decisions about treatments, but there’s currently no way to make such measurements. However, a new sensor developed at Massachusetts Institute of Technology could change that.
Delivering chemotherapy drugs in nanoparticle form could help reduce side effects by targeting the drugs directly to the tumors. In recent years, scientists have developed nanoparticles that deliver one or two chemotherapy drugs, but it has been difficult to design particles that can carry any more than that in a precise ratio. Now Massachusetts Institute of Technology chemists have devised a new way to build such nanoparticles.
A 10-year-old girl who died of brain cancer is leaving a legacy for other sick children in a new law signed by President Barack Obama. The legislation calls for eliminating taxpayer funding for political conventions and redirecting it to pediatric research at the National Institutes of Health.
Using magnetically controlled nanoparticles to force tumor cells to "self-destruct" sounds like science fiction, but could be a future part of cancer treatment, according to new research.
Chemotherapeutic drugs excel at fighting cancer, but they're not so efficient at getting where they need to go. Now, researchers are developing a better delivery method by encapsulating the drugs in nanoballoons – which are tiny modified liposomes that, upon being struck by a red laser, pop open and deliver concentrated doses of medicine.
A new understanding of proteins at the nexus of a cell’s decision to survive or die has implications for researchers who study cancer and age-related diseases, according to biophysicists at the Rice Univ.-based Center for Theoretical Biological Physics. Experiments and computer analysis of two key proteins revealed a previously unknown binding interface that could be addressed by medication.
Women with a faulty breast cancer gene might face a greater chance of rare but deadly uterine tumors despite having their ovaries removed to lower their main cancer risks, doctors are reporting. A study of nearly 300 women with bad BRCA1 genes found four cases of aggressive uterine cancers years after they had preventive surgery to remove their ovaries. That rate is 26 times greater than expected.
The delicate balance between development of normal tissue and tumors depends in part upon a key molecular switch within cells, Yale School of Medicine researchers report in Science. Their findings reveal a potential mechanism used by cancer cells to recruit healthy cells to promote tumor growth and suggest new strategies to generate healthy tissue.